172 related articles for article (PubMed ID: 22718313)
41. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
Le Mauff F; Mercier G; Chan P; Burel C; Vaudry D; Bardor M; Vézina LP; Couture M; Lerouge P; Landry N
Plant Biotechnol J; 2015 Jun; 13(5):717-25. PubMed ID: 25523794
[TBL] [Abstract][Full Text] [Related]
42. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
[TBL] [Abstract][Full Text] [Related]
43. Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro.
Zheng M; Jiang J; Zhang X; Wang N; Wang K; Li Q; Li T; Lin Q; Wang Y; Yu H; Gu Y; Zhang J; Li S; Xia N
Vaccine; 2018 Apr; 36(16):2104-2111. PubMed ID: 29544686
[TBL] [Abstract][Full Text] [Related]
44. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
45. The immunogenicity of the virus-like particles derived from the VP2 protein of porcine parvovirus.
Hua T; Zhang D; Tang B; Chang C; Liu G; Zhang X
Vet Microbiol; 2020 Sep; 248():108795. PubMed ID: 32827923
[TBL] [Abstract][Full Text] [Related]
46. Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation.
Wang J; Liu Y; Chen Y; Wang A; Wei Q; Liu D; Zhang G
Appl Microbiol Biotechnol; 2020 May; 104(9):3847-3857. PubMed ID: 32130468
[TBL] [Abstract][Full Text] [Related]
47. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
48. Production of a de-novo designed antimicrobial peptide in Nicotiana benthamiana.
Zeitler B; Bernhard A; Meyer H; Sattler M; Koop HU; Lindermayr C
Plant Mol Biol; 2013 Feb; 81(3):259-72. PubMed ID: 23242916
[TBL] [Abstract][Full Text] [Related]
49. Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
Simanavicius M; Tamosiunas PL; Petraityte-Burneikiene R; Johne R; Ulrich RG; Zvirbliene A; Kucinskaite-Kodze I
Appl Microbiol Biotechnol; 2018 Jan; 102(1):185-198. PubMed ID: 29143081
[TBL] [Abstract][Full Text] [Related]
50. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
[TBL] [Abstract][Full Text] [Related]
51. Mapping of linear B cell epitopes on capsid proteins of bovine papillomavirus: identification of three external type-restricted epitopes.
Cason J; Kambo PK; Jewers RJ; Chrystie IL; Best JM
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2669-77. PubMed ID: 8277272
[TBL] [Abstract][Full Text] [Related]
52. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations.
Lai H; Chen Q
Plant Cell Rep; 2012 Mar; 31(3):573-84. PubMed ID: 22134876
[TBL] [Abstract][Full Text] [Related]
53. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
54. Development of recombinant Yarrowia lipolytica producing virus-like particles of a fish nervous necrosis virus.
Luu VT; Moon HY; Hwang JY; Kang BK; Kang HA
J Microbiol; 2017 Aug; 55(8):655-664. PubMed ID: 28752293
[TBL] [Abstract][Full Text] [Related]
55. Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi.
Varsani A; Williamson AL; Rose RC; Jaffer M; Rybicki EP
Arch Virol; 2003 Sep; 148(9):1771-86. PubMed ID: 14505089
[TBL] [Abstract][Full Text] [Related]
56. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
57. Immunocompetent truncated E2 glycoprotein of bovine viral diarrhea virus (BVDV) expressed in Nicotiana tabacum plants: a candidate antigen for new generation of veterinary vaccines.
Nelson G; Marconi P; Periolo O; La Torre J; Alvarez MA
Vaccine; 2012 Jun; 30(30):4499-504. PubMed ID: 22554468
[TBL] [Abstract][Full Text] [Related]
58. Potent neutralization activity against type O foot-and-mouth disease virus elicited by a conserved type O neutralizing epitope displayed on bovine parvovirus virus-like particles.
Chang J; Zhang Y; Yang D; Jiang Z; Wang F; Yu L
J Gen Virol; 2019 Feb; 100(2):187-198. PubMed ID: 30547855
[TBL] [Abstract][Full Text] [Related]
59. Integrated molecular and bioprocess engineering for bacterially produced immunogenic modular virus-like particle vaccine displaying 18 kDa rotavirus antigen.
Tekewe A; Fan Y; Tan E; Middelberg AP; Lua LH
Biotechnol Bioeng; 2017 Feb; 114(2):397-406. PubMed ID: 27497268
[TBL] [Abstract][Full Text] [Related]
60. Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions.
Ghim SJ; Young R; Jenson AB
J Gen Virol; 1996 Feb; 77 ( Pt 2 )():183-8. PubMed ID: 8627221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
